We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biomarker Found for Prostate Cancer Treatment Response

By LabMedica International staff writers
Posted on 27 Nov 2018
Prostate cancer is one of the most common cancers in males and has one of the highest five-year survival rate when diagnosed in the localized stage. More...
When diagnosed in the advanced stage or when a localized tumor relapses after the initial local treatment, the usual procedure is to fight it using male hormone (androgen) deprivation therapy.

Treatment can be done either by surgical removal of the testicles or using medication that eliminates the testosterone production (chemical castration). However, many of the patients, up to 90%, after the initial castration develop more aggressive, castration-resistant forms and their survival rate is around two years. This most aggressive type of prostate cancer can be treated with two different therapies: taxanes or hormone treatment.

An international team of scientists led by the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS (Meldola, Italy) selected the 115 patients treated with docetaxel as first-line therapy and in an exploratory analysis compared them with 73 previously described patients treated with first-line abiraterone/enzalutamide. A comparison of clinicopathological characteristics between patients receiving either docetaxel or abiraterone/enzalutamide as first-line therapy showed significant differences in age, site of metastases.

The team measured prostate-specific antigen (PSA), lactate dehydrogenase (LDH), hemoglobin, alkaline phosphatase, and plasma androgen receptor (AR) status. Circulating DNA was extracted from plasma with the QIAamp Circulating Nucleic Acid Kit and quantified with the Quant-iT high sensitivity PicoGreen double-stranded DNA Assay Kit or by NanoDrop ND-1000 spectrophotometric evaluation.

The scientists determined that castration-resistant prostate cancer patients having a normal number of copies of the gene encoding the androgen receptor (AR), the one regulating cellular signals mediated by male sex hormones, in the circulating tumor DNA, seem to have a lower risk of disease progression and a higher life expectancy when they are treated with abiraterone/enzalutamide, with a 50% higher survival rate compared to docetaxel, where the average life expectancy was around 24 months. On the other hand, the patients with more copies of the androgen receptor gene respond slightly better to docetaxel, with a higher life expectancy, around nine months, compared to abiraterone/enzalutamide.

The authors concluded that their findings suggest that AR gain detected in plasma is associated with resistance to abiraterone/enzalutamide but not with taxanes when used in the first-line setting. In conclusion, prospective randomized trials are warranted to validate the utility of plasma AR status for treatment selection in metastatic castration-resistant prostate cancer patients. The study was published on October 26, 2018, in the journal European Urology.

Related Links:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
Gel Cards
DG Gel Cards
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.